Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Mantle Cell and NHL (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 19, 2008
Cole & Pfizer: Happy together in NSCLCA (non small cell lung cancer)
Analysis of: Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
"The investigator-assessed objective response rate (complete and partial response), including both confirmed and unconfirmed responses, was 38% in the PF-3512676 plus chemotherapy arm and 19% in the chemotherapy-alone arm (P = .043)." In other words. IT MAY WORK!
August 13, 2008
"Health-care costs are expected to rise more than 10% ".... and we can continue this for how long??
Analysis of: Insurers Expect Health-Care Costs To Rise More Than 10% Next Year | online.wsj.com
Author: GLG Expert Contributor
10% increase in medical spending when the overall cost of living is 1/2 of medical costs and we are happy??
August 11, 2008
Fair or Unfair Decision: the cost of the drugs for kidney cancer is more than the economy can bear.
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: GLG Expert Contributor
Pfizer’s Sutent, Wyeth’s Torisel, Bayer’s Nexavar and Avastin, sold by Roche and Genentech have been deemed too expensive to be paid for by UK agencies
August 7, 2008
Salmonella; Cancer cells?? Let's not get carried away
Analysis of: Salmonella Is Tested To Fight Cancer Cells | online.wsj.com
Author: GLG Expert Contributor
Salmonella targeting cancer cells? In humans???
August 6, 2008
Boy will this p.... off Urologists as well as AARP!
Analysis of: Panel Urges End to Prostate Screening at Age 75 | www.nytimes.com
Author: GLG Expert Contributor
Since treatment may be worse than the disease it is being recommended that routine prostate cancer screening be stopped after the age of 75.
August 6, 2008
Cancer Diagnosis and Treatment Among High Profile Celebrities and Public Figures
Analysis of: Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
Author: GLG Expert Contributor
Nothing fascinates the public interest and imagination more than news about prominent and famous media stars who suffer illness or disaster. This is the way things are, but perhaps, at least in the case of healthcare issues, it could be beneficial to society to discuss these cases in detail, from both...
July 31, 2008
Amgen and J & J: Not hurt as much as we had predicted.
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
Amgens Aranesp sales fell 26% and J & J's Procrit sales fell 23%."Yaron Werber, a biotechnology analyst at Citi Investment Research, estimated that the new label could reduce the use of Aranesp for cancer patients in this country — the drug is also used by people with kidney disease — by an additional...
July 31, 2008
Lung Cancer Screening: Here we go again.
Analysis of: Corrections Weaken Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Lung cancer screening does not appear to prevent death at least in this study.
July 30, 2008
Avastin may not get approval of "cost-conscious" EMEA
Analysis of: Roche Files Avastin for Wider Label in EU | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Avastin ( Roche/Genentech) extended time to progression when combined with Docotaxel ( Sanofi-Aventis) in patients with metastatic breast cancer as compared to Docotaxel alone, but did not prolong survival. Unlike approval by the FDA,the EMEA is more cost conscious and may be reluctant to...
July 29, 2008
Avastin use in breast ca in the EU? No surprise but does it prolong survival?? Who is the winner??
Analysis of: Roche Files Avastin for Wider Label in EU | www.therapeuticsdaily.com
Author: GLG Expert Contributor
"The filing is supported by data from the phase III Avado trial, which investigated Avastin in combination with docetaxel compared wwith docetaxel alone in the first-line treatment of patients with metastatic breast cancer, Roche said in a statement."

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 764

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637